$INTI
Inhibitor Therapeutics, Inc.

2015 Q1 Form 10-K Financial Statement

#000119312515050220 Filed on February 13, 2015

View on sec.gov

Income Statement

Concept 2015 Q1 2013 Q4 2013
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $610.0K $200.0K $820.0K
YoY Change 281.25% -16.67% 46.43%
% of Gross Profit
Research & Development $313.0K $20.00K $1.065M
YoY Change 1136.0%
% of Gross Profit
Depreciation & Amortization $0.00
YoY Change
% of Gross Profit
Operating Expenses $922.7K $210.0K $2.000M
YoY Change 393.59% -12.5% 256.68%
Operating Profit -$922.7K -$2.000M
YoY Change 393.59% 256.68%
Interest Expense $0.00 $0.00 $1.923K
YoY Change -100.0% -100.0% -97.6%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$920.0K -$220.0K -$1.840M
YoY Change 360.0% 0.0% -1068.42%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$922.7K -$220.0K -$1.835M
YoY Change 369.58% 0.0% -1084.65%
Net Earnings / Revenue
Basic Earnings Per Share -$0.10
Diluted Earnings Per Share $0.00 -$0.01 -$0.10
COMMON SHARES
Basic Shares Outstanding 211.4M shares 18.89M shares 17.94M shares
Diluted Shares Outstanding 17.94M shares

Balance Sheet

Concept 2015 Q1 2013 Q4 2013
SHORT-TERM ASSETS
Cash & Short-Term Investments $80.00K $0.00 $0.00
YoY Change -100.0% -100.0%
Cash & Equivalents $83.95K $217.00 $0.00
Short-Term Investments
Other Short-Term Assets $43.72K $10.00K
YoY Change 337.23% -87.5%
Inventory
Prepaid Expenses $10.00K
Receivables
Other Receivables
Total Short-Term Assets $127.7K $10.22K $10.00K
YoY Change 1121.06% -98.91% -98.94%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $127.7K $10.22K $10.00K
Total Long-Term Assets $0.00 $0.00 $0.00
Total Assets $127.7K $10.22K $10.00K
YoY Change 1121.06% -98.91% -98.94%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $493.9K $287.1K $290.0K
YoY Change 39.08% -22.12% -21.62%
Accrued Expenses $0.00 $0.00
YoY Change -100.0% -100.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $70.00K $70.00K
YoY Change -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $568.6K $776.1K $780.0K
YoY Change -41.55% 38.59% 39.29%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $0.00
YoY Change -100.0% -100.0%
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $568.6K $776.1K $780.0K
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $568.6K $776.1K $780.0K
YoY Change -41.38% -27.42% -27.1%
SHAREHOLDERS EQUITY
Retained Earnings -$33.15M -$28.25M
YoY Change 16.53% 6.95%
Common Stock $32.70M $1.889K
YoY Change 1731225.3%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$440.9K -$765.8K -$770.0K
YoY Change
Total Liabilities & Shareholders Equity $127.7K $10.22K $10.00K
YoY Change 1121.06% -98.91% -98.94%

Cashflow Statement

Concept 2015 Q1 2013 Q4 2013
OPERATING ACTIVITIES
Net Income -$922.7K -$220.0K -$1.835M
YoY Change 369.58% 0.0% -1084.65%
Depreciation, Depletion And Amortization $0.00
YoY Change
Cash From Operating Activities -$280.0K -$170.0K -$1.224M
YoY Change 154.55% 183.33% 163.56%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 170.0K 366.1K
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -280.0K -170.0K -1.224M
Cash From Investing Activities
Cash From Financing Activities 0.000 170.0K 366.1K
Net Change In Cash -280.0K 0.000 -857.5K
YoY Change -100.0% 84.7%
FREE CASH FLOW
Cash From Operating Activities -$280.0K -$170.0K -$1.224M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
211419937 shares
CY2014Q2 dei Entity Public Float
EntityPublicFloat
1776288
CY2011Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.02
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
245443 shares
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
-132784
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
857702
CY2013Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
18888971 shares
CY2013Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
18888971 shares
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
340000000 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0
CY2013Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2013Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2013Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
9500000 shares
CY2013Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2013Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
0 shares
CY2013Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
52500
CY2013Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
756783
CY2013Q4 us-gaap Liabilities Current
LiabilitiesCurrent
776053
CY2013Q4 us-gaap Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
68428
CY2013Q4 us-gaap Interest Payable Current
InterestPayableCurrent
1923
CY2013Q4 us-gaap Common Stock Value
CommonStockValue
1889
CY2013Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2013Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
287072
CY2013Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-28247655
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
-765836
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
10217
CY2013Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
27479913
CY2013Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
366130
CY2013Q4 us-gaap Liabilities
Liabilities
776053
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
217
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0
CY2013Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
756783
CY2013Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
2584
CY2013Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
407398
CY2013Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
346801
CY2013Q4 us-gaap Assets
Assets
10217
CY2013Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2013Q4 us-gaap Assets Current
AssetsCurrent
10217
CY2013Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
10000
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
211419937 shares
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
211419937 shares
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
340000000 shares
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0
CY2014Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2014Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
9500000 shares
CY2014Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2014Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
0 shares
CY2014Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
75933
CY2014Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
2164708
CY2014Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
400899
CY2014Q4 us-gaap Common Stock Value
CommonStockValue
21142
CY2014Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2014Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
324966
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-32222953
CY2014Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
73178
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
62079
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
462978
CY2014Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
32263890
CY2014Q4 us-gaap Liabilities
Liabilities
400899
CY2014Q4 us-gaap Assets
Assets
462978
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
365161
CY2014Q4 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000
CY2014Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
15779
CY2014Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
256219
CY2014Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
878706
CY2014Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
996154
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0
CY2014Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
2164708
CY2014Q4 us-gaap Cash Uninsured Amount
CashUninsuredAmount
15000
CY2014Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
17850
CY2014Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2014Q4 us-gaap Assets Current
AssetsCurrent
462978
CY2014Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
97817
CY2014Q4 hppi Net Operating Loss Amount Used To Offset Against Taxable Income
NetOperatingLossAmountUsedToOffsetAgainstTaxableIncome
35000
CY2013Q1 hppi Ownership Exchanged For Assets Contributed
OwnershipExchangedForAssetsContributed
0.90 pure
CY2013Q1 hppi Percentage Of Issued And Outstanding Shares Of Common Stock
PercentageOfIssuedAndOutstandingSharesOfCommonStock
1.00 pure
CY2013 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
CY2013 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-1223615
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
245443 shares
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0 shares
CY2013 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
17940586 shares
CY2013 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
3.02
CY2013 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0
CY2013 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.10
CY2013 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
CY2013 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1050004
CY2013 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
152000
CY2013 us-gaap Operating Income Loss
OperatingIncomeLoss
-1999809
CY2013 us-gaap Notes Issued1
NotesIssued1
68428
CY2013 us-gaap Revenues
Revenues
0
CY2013 us-gaap Net Income Loss
NetIncomeLoss
-1835056
CY2013 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-68733
CY2013 us-gaap Debtor Reorganization Items Other Expense Income
DebtorReorganizationItemsOtherExpenseIncome
117324
CY2013 us-gaap Interest Expense
InterestExpense
1923
CY2013 us-gaap Operating Expenses
OperatingExpenses
1999809
CY2013 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1065169
CY2013 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-857485
CY2013 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-627319
CY2013 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2013 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
46645
CY2013 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
366130
CY2013 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-63688
CY2013 us-gaap Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
366130
CY2013 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
817316
CY2013 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
691007
CY2013 hppi Increase Decrease In Liabilities Subject To Compromise
IncreaseDecreaseInLiabilitiesSubjectToCompromise
-357265
CY2013 hppi Bankruptcy Claims Settlement In Equity
BankruptcyClaimsSettlementInEquity
152000
CY2013 hppi Gain Loss On Reorganization
GainLossOnReorganization
166676
CY2013 hppi Deposit Reclassified To Preferred Stock
DepositReclassifiedToPreferredStock
30000
CY2013 hppi Net Cash Provided By Operating Activities Before Reorganization Items
NetCashProvidedByOperatingActivitiesBeforeReorganizationItems
-699674
CY2013 hppi Bankruptcy Claims Settlement In Cash
BankruptcyClaimsSettlementInCash
357265
CY2013 hppi Period Consider For Average Equity Stock Price Calculation Per Share
PeriodConsiderForAverageEquityStockPriceCalculationPerShare
P30D
CY2013 hppi In Process Research And Development Paid In Stock And Warrants
InProcessResearchAndDevelopmentPaidInStockAndWarrants
1020004
CY2014 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
CY2014 dei Document Type
DocumentType
10-K
CY2014 dei Entity Registrant Name
EntityRegistrantName
HedgePath Pharmaceuticals, Inc.
CY2014 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2014 dei Trading Symbol
TradingSymbol
HPPI
CY2014 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 30px; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <b><i>Estimates</i></b></p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 30px; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.</p> </div>
CY2014 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
95884524 shares
CY2014 dei Document Period End Date
DocumentPeriodEndDate
2014-12-31
CY2014 us-gaap Share Based Compensation
ShareBasedCompensation
753585
CY2014 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
1407921
CY2014 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2014 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2014 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y
CY2014 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-1303524
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0 shares
CY2014 dei Amendment Flag
AmendmentFlag
false
CY2014 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2014 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2014
CY2014 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0
CY2014 dei Entity Central Index Key
EntityCentralIndexKey
0001042418
CY2014 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.04
CY2014 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2014 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
CY2014 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2014 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
250000
CY2014 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
753585
CY2014 us-gaap Operating Income Loss
OperatingIncomeLoss
-3937817
CY2014 us-gaap Stock Issued During Period Value Purchase Of Assets
StockIssuedDuringPeriodValuePurchaseOfAssets
619134
CY2014 us-gaap Revenues
Revenues
0
CY2014 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
105170
CY2014 us-gaap Net Income Loss
NetIncomeLoss
-3975298
CY2014 us-gaap Interest Paid
InterestPaid
2005
CY2014 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
450000
CY2014 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
87817
CY2014 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
80899
CY2014 us-gaap Interest Expense
InterestExpense
37481
CY2014 us-gaap Operating Expenses
OperatingExpenses
3937817
CY2014 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2430735
CY2014 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
364944
CY2014 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-1351601
CY2014 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2014 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
61327
CY2014 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
1668468
CY2014 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1500000
CY2014 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-137219
CY2014 us-gaap Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
273638
CY2014 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1507082
CY2014 hppi Issuance Of Preferred Stock
IssuanceOfPreferredStock
1290726
CY2014 hppi Gain Loss On Reorganization
GainLossOnReorganization
0
CY2014 hppi Net Cash Provided By Operating Activities Before Reorganization Items
NetCashProvidedByOperatingActivitiesBeforeReorganizationItems
-1303524
CY2014 hppi Stock Issued During Period Value Debt Forgiveness
StockIssuedDuringPeriodValueDebtForgiveness
189768
CY2014 hppi Noncash Interest Expense
NoncashInterestExpense
34819
CY2014 hppi Supply And License Agreement Term Duration From First Commercial Transaction
SupplyAndLicenseAgreementTermDurationFromFirstCommercialTransaction
P10Y
CY2014 hppi In Process Research And Development Paid In Stock And Warrants
InProcessResearchAndDevelopmentPaidInStockAndWarrants
1909860
CY2014 hppi Collection Of Stock Subscription Receivable
CollectionOfStockSubscriptionReceivable
1250000

Files In Submission

Name View Source Status
0001193125-15-050220-index-headers.html Edgar Link pending
0001193125-15-050220-index.html Edgar Link pending
0001193125-15-050220.txt Edgar Link pending
0001193125-15-050220-xbrl.zip Edgar Link pending
d831773d10k.htm Edgar Link pending
d831773dex14.htm Edgar Link pending
d831773dex311.htm Edgar Link pending
d831773dex312.htm Edgar Link pending
d831773dex321.htm Edgar Link pending
d831773dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
hppi-20141231.xml Edgar Link completed
hppi-20141231.xsd Edgar Link pending
hppi-20141231_cal.xml Edgar Link unprocessable
hppi-20141231_def.xml Edgar Link unprocessable
hppi-20141231_lab.xml Edgar Link unprocessable
hppi-20141231_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending